Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
|---|---|---|---|---|---|
| FGB-H5259 | Human | Human FGF R3 (IIIb) / FGF R3B / CD333 Protein, Fc Tag (MALS verified) |  |
|
Human FGF R3 (IIIb), Fc Tag (Cat. No. FGB-H5259) immobilized on CM5 Chip can bind Human FGF acidic, Tag Free (Cat. No. AFF-H4116) with an affinity constant of 5.91 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
The purity of Human FGF R3 (IIIb), Fc Tag (Cat. No. FGB-H5259) is more than 90% and the molecular weight of this protein is around 132-162 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Sarcoma, Alveolar Soft Part; Bile Duct Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Hepatic Insufficiency; Bone Neoplasms; Urologic Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Medullary thyroid cancer (MTC); Gallbladder Neoplasms; Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Osteoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Leiomyosarcoma; Solid tumours; Drug-Related Side Effects and Adverse Reactions; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Nasopharyngeal Carcinoma | Details |
| Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Carcinoma, Adenoid Cystic; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Neuroendocrine Tumors; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Kidney Diseases; Neoplasms; Pheochromocytoma; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors | Details |
| Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Pemigatinib | INCB-054828; INCB-54828; IBI-375 | Approved | Incyte Corp | Pemazyre, 伯坦, 达伯坦 | United States | Cholangiocarcinoma | Incyte Corp | 2020-04-17 | Multiple Myeloma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Glioma; Lung Neoplasms; Lymphoma; Colitis, Ulcerative; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Cholangiocarcinoma; Translocation, Genetic; Breast Neoplasms; Bone Marrow Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Myeloproliferative Disorders; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Biliary Tract Neoplasms; Solid tumours | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a | Details |
| Erdafitinib | G-024; JNJ-493; JNJ-42756493; TAR-210; 890E37NHMV | Approved | Astex Pharmaceuticals Inc | Balversa | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Breast Neoplasms; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Histiocytosis, Langerhans-Cell; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Transitional Cell; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Ependymoma; Bone metastases; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Neoplasms; Wilms Tumor; Glioblastoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Osteosarcoma | Details |
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Sarcoma, Alveolar Soft Part; Bile Duct Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Hepatic Insufficiency; Bone Neoplasms; Urologic Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Medullary thyroid cancer (MTC); Gallbladder Neoplasms; Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Osteoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Leiomyosarcoma; Solid tumours; Drug-Related Side Effects and Adverse Reactions; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Nasopharyngeal Carcinoma | Details |
| Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Carcinoma, Adenoid Cystic; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Neuroendocrine Tumors; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Kidney Diseases; Neoplasms; Pheochromocytoma; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors | Details |
| Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Pemigatinib | INCB-054828; INCB-54828; IBI-375 | Approved | Incyte Corp | Pemazyre, 伯坦, 达伯坦 | United States | Cholangiocarcinoma | Incyte Corp | 2020-04-17 | Multiple Myeloma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Glioma; Lung Neoplasms; Lymphoma; Colitis, Ulcerative; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Cholangiocarcinoma; Translocation, Genetic; Breast Neoplasms; Bone Marrow Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Myeloproliferative Disorders; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Biliary Tract Neoplasms; Solid tumours | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a | Details |
| Erdafitinib | G-024; JNJ-493; JNJ-42756493; TAR-210; 890E37NHMV | Approved | Astex Pharmaceuticals Inc | Balversa | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Breast Neoplasms; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Histiocytosis, Langerhans-Cell; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Transitional Cell; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Ependymoma; Bone metastases; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Neoplasms; Wilms Tumor; Glioblastoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Osteosarcoma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| Fexagratinib | AZD4547; AZD-4547; ABSK-091; ABSK091 | Phase 3 Clinical | Astrazeneca Plc | Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Urinary Bladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms | Details |
| Infigratinib | BGJ-398; NVP-BGJ398 | Phase 3 Clinical | Novartis Pharma Ag | Papillomavirus Infections; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Biliary Tract Neoplasms; Neoplasms; Achondroplasia; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours | Details |
| Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
| SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Zoligratinib | CH-5183284; FF-284; Debio-1347 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms | Details |
| Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
| HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 2 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours; Cholangiocarcinoma | Details |
| TYRA-300 | TYRA300 | Phase 2 Clinical | Tyra Biosciences Inc | Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms | Details |
| SAR-442501 | SAR-442501 | Phase 2 Clinical | Sanofi | Osteochondrodysplasias; Achondroplasia | Details |
| HMPL-453 | HMPL-453 | Phase 2 Clinical | Hutchison Medipharma Ltd | Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma | Details |
| Tasurgratinib | E-7090 | Phase 2 Clinical | Eisai Co Ltd | Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency | Details |
| Sprifermin | rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 | Phase 2 Clinical | Zymogenetics Inc | Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee | Details |
| Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
| Recifercept | PF-07256472; TA-46 | Phase 1 Clinical | Pfizer Inc | Achondroplasia | Details |
| BPI-17509 | BPI-17509 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| TYRA-200 | TYRA200; TYRA-200 | Phase 1 Clinical | Tyra Biosciences Inc | Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms | Details |
| Resigratinib | KIN-3248; KIN-003 | Phase 1 Clinical | Kinnate Biopharma Inc | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma | Details |
| TYRA-300-B01 | TYRA-300-B01 | Phase 1 Clinical | Tyra Biosciences Inc | Details | |
| LOXO-435 | LOXO-435 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Neoplasms; Urinary Bladder Neoplasms; Ureteral Neoplasms; Neoplasm Metastasis | Details |
| TT-00434 | TT-00434 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours; Urinary Bladder Neoplasms | Details |
| ABSK-121 | ABSK121-NX; ABSK121 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
| ABSK-061 | ABSK061 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
| LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
| CPL-304110 | CPL-304110; CPL-304-110 | Phase 1 Clinical | Celon Pharma Sa | Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| Fexagratinib | AZD4547; AZD-4547; ABSK-091; ABSK091 | Phase 3 Clinical | Astrazeneca Plc | Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Urinary Bladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms | Details |
| Infigratinib | BGJ-398; NVP-BGJ398 | Phase 3 Clinical | Novartis Pharma Ag | Papillomavirus Infections; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Biliary Tract Neoplasms; Neoplasms; Achondroplasia; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours | Details |
| Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
| SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Zoligratinib | CH-5183284; FF-284; Debio-1347 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms | Details |
| Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
| HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 2 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours; Cholangiocarcinoma | Details |
| TYRA-300 | TYRA300 | Phase 2 Clinical | Tyra Biosciences Inc | Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms | Details |
| SAR-442501 | SAR-442501 | Phase 2 Clinical | Sanofi | Osteochondrodysplasias; Achondroplasia | Details |
| HMPL-453 | HMPL-453 | Phase 2 Clinical | Hutchison Medipharma Ltd | Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma | Details |
| Tasurgratinib | E-7090 | Phase 2 Clinical | Eisai Co Ltd | Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency | Details |
| Sprifermin | rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 | Phase 2 Clinical | Zymogenetics Inc | Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee | Details |
| Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
| Recifercept | PF-07256472; TA-46 | Phase 1 Clinical | Pfizer Inc | Achondroplasia | Details |
| BPI-17509 | BPI-17509 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| TYRA-200 | TYRA200; TYRA-200 | Phase 1 Clinical | Tyra Biosciences Inc | Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms | Details |
| Resigratinib | KIN-3248; KIN-003 | Phase 1 Clinical | Kinnate Biopharma Inc | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma | Details |
| TYRA-300-B01 | TYRA-300-B01 | Phase 1 Clinical | Tyra Biosciences Inc | Details | |
| LOXO-435 | LOXO-435 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Neoplasms; Urinary Bladder Neoplasms; Ureteral Neoplasms; Neoplasm Metastasis | Details |
| TT-00434 | TT-00434 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours; Urinary Bladder Neoplasms | Details |
| ABSK-121 | ABSK121-NX; ABSK121 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
| ABSK-061 | ABSK061 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
| LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
| CPL-304110 | CPL-304110; CPL-304-110 | Phase 1 Clinical | Celon Pharma Sa | Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
